Artivion's Q3 Net Income Soars on Strong Product Sales, Debt Reduction

TL;DR

**AORT is looking strong with surging profits and a leaner balance sheet; time to buy the dip if you haven't already.**

AI Summary

ARTIVION, INC. (AORT) reported a significant increase in net income for the three months ended September 30, 2025, reaching $6.502 million, a substantial improvement from a net loss of $2.288 million in the same period of 2024. Total revenues grew to $113.388 million, up from $95.779 million year-over-year, primarily driven by product revenues increasing from $71.244 million to $87.665 million. For the nine months ended September 30, 2025, net income was $7.342 million, compared to $3.124 million in 2024, on total revenues of $325.338 million, up from $291.229 million. The company recognized a pre-tax gain of $3.5 million from a PerClot sales milestone in Q3 2025. Operating income for the quarter surged to $12.536 million from $4.387 million in Q3 2024. Long-term debt decreased significantly from $314.152 million at December 31, 2024, to $214.869 million at September 30, 2025. Cash and cash equivalents increased by $19.963 million to $73.426 million during the nine-month period. The company also early adopted ASU 2024-04 regarding induced conversions of convertible debt instruments as of June 30, 2025.

Why It Matters

Artivion's robust Q3 performance, marked by a significant jump in net income and revenue, signals strong operational execution and potential market share gains in the medical device sector. The substantial reduction in long-term debt by nearly $100 million enhances financial stability and reduces interest expense, which is crucial for investor confidence. This financial health could enable further R&D investments or strategic acquisitions, intensifying competition with rivals like Baxter International. For employees, this growth could mean job security and expansion opportunities, while customers may benefit from continued innovation in cardiovascular and surgical products. The positive financial trajectory could also attract more institutional investment, impacting AORT's stock valuation.

Risk Assessment

Risk Level: medium — While Artivion shows strong financial improvements, the company still operates with a retained deficit of $53.924 million as of September 30, 2025, indicating historical losses. Additionally, the contingent consideration liabilities, totaling $18.730 million current and $36.540 million non-current, represent potential future cash outflows that could impact liquidity, despite the overall debt reduction.

Analyst Insight

Investors should consider Artivion's improved profitability and significant debt reduction as positive indicators. The strong product revenue growth and the PerClot sales milestone suggest operational momentum. Monitor future contingent consideration payments and the impact of new accounting standards on disclosures, but the current trajectory suggests a favorable outlook for long-term holders.

Financial Highlights

revenue

$113.388M

operating Margin

11.06%

total Assets

$857.662M

total Debt

$214.869M

net Income

$6.502M

eps

$0.13

gross Margin

65.61%

cash Position

$73.426M

revenue Growth

+18.38%

Revenue Breakdown

Key Numbers

• $6.502M — Net Income (Q3 2025) (Increased from a net loss of $2.288M in Q3 2024)
• $113.388M — Total Revenues (Q3 2025) (Up from $95.779M in Q3 2024, a 18.38% increase)
• $87.665M — Product Revenues (Q3 2025) (Increased from $71.244M in Q3 2024, a 23.04% increase)
• $3.5M — Gain from sale of non-financial assets (Q3 2025) (Recognized from PerClot sales milestone)
• $12.536M — Operating Income (Q3 2025) (Significantly up from $4.387M in Q3 2024, a 185.76% increase)
• $214.869M — Long-term debt (Sept 30, 2025) (Decreased from $314.152M at Dec 31, 2024, a 31.59% reduction)
• $73.426M — Cash and cash equivalents (Sept 30, 2025) (Increased from $53.463M at Dec 31, 2024, a 37.34% increase)
• $0.13 — Diluted EPS (Q3 2025) (Improved from $(0.05) in Q3 2024)

Key Players & Entities

• ARTIVION, INC. (company) — registrant
• Baxter International, Inc. (company) — purchaser of PerClot
• Endospan Ltd. (company) — distribution partner and acquisition target
• JOTEC (company) — wholly owned subsidiary of Artivion
• SMI (company) — Starch Medical, Inc., partner in PerClot transaction
• FDA (regulator) — US Food and Drug Administration
• $6.502 million (dollar_amount) — net income for three months ended September 30, 2025
• $2.288 million (dollar_amount) — net loss for three months ended September 30, 2024
• $113.388 million (dollar_amount) — total revenues for three months ended September 30, 2025
• $214.869 million (dollar_amount) — long-term debt as of September 30, 2025

FAQ

Risk Factors

• Debt Management and Interest Expense [medium — financial]: The company has a significant amount of long-term debt, which decreased from $314.152 million at December 31, 2024, to $214.869 million at September 30, 2025. Despite the reduction, interest expense was $6.119 million in Q3 2025, impacting profitability.
• Supply Chain and Cost of Goods Sold [medium — operational]: The cost of products and preservation services increased to $38.993 million in Q3 2025 from $34.770 million in Q3 2024. Fluctuations in these costs can impact gross margins.
• Adoption of New Accounting Standards [low — regulatory]: Artivion early adopted ASU 2024-04 regarding induced conversions of convertible debt instruments. While this may offer benefits, it introduces complexity and potential for unforeseen accounting implications.
• Competition in Medical Devices [medium — market]: The company operates in the competitive medical device market. Success depends on innovation, market penetration, and managing relationships with healthcare providers.
• Foreign Currency Translation [low — financial]: The company experienced significant foreign currency translation adjustments, with $541 million in other comprehensive income for Q3 2025, compared to $6.333 million in Q3 2024. This volatility can affect reported comprehensive income.

Industry Context

Artivion operates in the medical device sector, specifically focusing on cardiovascular and surgical products. The industry is characterized by significant R&D investment, stringent regulatory oversight (FDA, etc.), and a competitive landscape with established players and emerging innovators. Trends include the development of minimally invasive technologies and personalized medicine solutions.

Regulatory Implications

The company must adhere to strict regulations from bodies like the FDA for its medical devices. Compliance with accounting standards, such as the early adoption of ASU 2024-04, is also critical. Any product recalls, adverse event reporting, or changes in healthcare policy can have significant financial and operational impacts.

What Investors Should Do

1. Monitor debt reduction progress and interest expense.
2. Analyze the sustainability of product revenue growth.
3. Assess the impact of the PerClot milestone gain.
4. Evaluate operating expense management.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant net income increase to $6.502M and revenue growth to $113.388M, driven by product sales and a $3.5M milestone gain.
• 2025-09-30: End of Nine Months 2025 — Total revenues reached $325.338M, net income was $7.342M, and long-term debt reduced substantially to $214.869M.
• 2025-06-30: Early adoption of ASU 2024-04 — Company adopted new accounting guidance for induced conversions of convertible debt, effective from this date.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $2.288M and revenues of $95.779M, providing a baseline for the current period's strong performance.
• 2024-12-31: End of Fiscal Year 2024 — Long-term debt stood at $314.152M, serving as a reference point for the significant debt reduction achieved by September 30, 2025.

Glossary

PerClot sales milestone

A pre-defined sales target or achievement related to the PerClot product, triggering a financial gain for the company. (Contributed $3.5 million to pre-tax income in Q3 2025, positively impacting net income.)

ASU 2024-04

Accounting Standards Update 2024-04, which provides guidance on accounting for induced conversions of convertible debt instruments. (Artivion early adopted this standard, affecting how convertible debt conversions are recognized in their financial statements.)

Operating income

Profitability from a company's core business operations before interest and taxes. (Surged to $12.536 million in Q3 2025 from $4.387 million in Q3 2024, indicating improved operational efficiency.)

Gross margin

The difference between revenue and the cost of goods sold, expressed as a percentage of revenue. (Increased to 65.61% in Q3 2025 from 63.90% in Q3 2024, showing better cost management relative to sales.)

Diluted EPS

Earnings per share calculated after accounting for all potential dilutive securities, such as stock options and convertible bonds. (Improved to $0.13 in Q3 2025 from $(0.05) in Q3 2024, reflecting increased profitability on a per-share basis.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Artivion has demonstrated a remarkable turnaround. Total revenues grew by 18.38% to $113.388 million, driven by a strong 23.04% increase in product revenues. This top-line growth, coupled with a significant gain from a sales milestone and improved operational efficiency, resulted in a swing from a net loss of $2.288 million to a net income of $6.502 million. Furthermore, the company has made substantial progress in deleveraging, reducing long-term debt by over 31%.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value AORT New York Stock Exchange

Filing Documents

• aort-20250930.htm (10-Q) — 1318KB
• aort-20250930xex311.htm (EX-31.1) — 9KB
• aort-20250930xex312.htm (EX-31.2) — 9KB
• aort-20250930xex32.htm (EX-32) — 6KB
• 0001628280-25-050502.txt ( ) — 6596KB
• aort-20250930.xsd (EX-101.SCH) — 46KB
• aort-20250930_cal.xml (EX-101.CAL) — 67KB
• aort-20250930_def.xml (EX-101.DEF) — 222KB
• aort-20250930_lab.xml (EX-101.LAB) — 597KB
• aort-20250930_pre.xml (EX-101.PRE) — 404KB
• aort-20250930_htm.xml (XML) — 833KB

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. 3 Condensed Consolidated Statements of Operations and Comprehensive Income 3 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Stockholders' Equity 6 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 24

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 35

Controls and Procedures

Item 4. Controls and Procedures. 35

– OTHER INFORMATION

Part II – OTHER INFORMATION 37

Legal Proceedings

Item 1. Legal Proceedings. 37

Risk Factors

Item 1A. Risk Factors. 37

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 50

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities. 50

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 50

Other Information

Item 5. Other Information. 51

Exhibits

Item 6. Exhibits. 52

Signatures

Signatures 53 2 Table of Contents

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Artivion, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Income In Thousands, Except Per Share Data (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues: Products $ 87,665 $ 71,244 $ 253,907 $ 215,568 Preservation services 25,723 24,535 71,431 75,661 Total revenues 113,388 95,779 325,338 291,229 Cost of products and preservation services: Products 27,811 24,412 81,389 72,707 Preservation services 11,182 10,358 32,865 31,243 Total cost of products and preservation services 38,993 34,770 114,254 103,950 Gross margin 74,395 61,009 211,084 187,279 Operating expenses: General, administrative, and marketing 57,281 50,017 169,650 130,026 Research and development 8,078 6,605 21,869 21,048 Total operating expenses 65,359 56,622 191,519 151,074 Gain from sale of non-financial assets ( 3,500 ) — ( 3,500 ) — Operating income 12,536 4,387 23,065 36,205 Interest expense 6,119 8,405 21,052 24,535 Interest income ( 240 ) ( 366 ) ( 452 ) ( 1,093 ) Losses on inducement/extinguishment of debt — — 2,664 3,669 Other (income) expense, net ( 399 ) ( 2,386 ) ( 8,442 ) 6 Income (loss) before income taxes 7,056 ( 1,266 ) 8,243 9,088 Income tax expense 554 1,022 901 5,964 Net income (loss) $ 6,502 $ ( 2,288 ) $ 7,342 $ 3,124 Income (loss) per share: Basic $ 0.14 $ ( 0.05 ) $ 0.16 $ 0.07 Diluted $ 0.13 $ ( 0.05 ) $ 0.16 $ 0.07 Weighted-average common shares outstanding: Basic 47,233 41,844 44,605 41,607 Diluted 48,775 41,844 45,993 42,621 Net income (loss) $ 6,502 $ ( 2,288 ) $ 7,342 $ 3,124 Other comprehensive income: Foreign currency translation adjustments, net of tax 541 6,333 22,640 2,482 Comprehensive income $ 7,043 $ 4,045 $ 29,982 $ 5,606 See accompanying Notes to Condensed Consolidated Financial Statements 3 Table of Contents Artivion, Inc. and Subsidiaries Condensed Consolidated Balance Sheets In Thousands

View Full Filing

View this 10-Q filing on SEC EDGAR